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Introduction
Deep brain stimulation of the subthalamic nucleus (STN DBS) is a well-established surgical treatment for Parkinson disease. Efficacious therapy requires both accurate surgical placement of DBS leads and careful programming of stimulation parameters. Together, these procedures ensure modulation of the correct neural pathways to achieve maximal therapeutic effect.
However, conventional DBS programming to achieve optimal tissue activation is a timeconsuming empirical process [1, 2] .
There exist both anatomical and electrophysiological approaches to prospectively identify therapeutic activation regions. Clinical observations [3] [4] [5] and computational models [6] [7] [8] both point to dorsal STN as an effective stimulation target. This region is traversed by the hyperdirect pathway [9] , which has been strongly implicated in the therapeutic mechanisms of DBS [10, 11] .
Tissue activation models, in particular, have made notable contributions to this area of study.
Although in vivo measurement of tissue activation is typically impractical, tissue activation models offer a sophisticated estimate of the anatomical region activated by therapeutic stimulation [12, 13] and have strengthened hypotheses identifying dorsal STN and the hyperdirect pathway as optimal sites of stimulation [6, 8] . Regions of elevated beta power observed on microelectrode recording have also been associated with effective DBS [14] [15] [16] [17] [18] [19] [20] [21] and are often coincident with dorsal STN [17, 22, 23] .
However, a growing body of evidence suggests that this is not the complete story. While the "average" active contact is often located near the dorsal STN border, maximally effective stimulation sites are known to vary significantly across patients [24, 25] . This highlights a need to more precisely characterize the three-dimensional span of tissue activated by therapeutic stimulation, which has historically been analyzed as a solitary point [15, 16, 18, 19] . Likewise, a number of subthalamic oscillations outside the beta band-notably alpha, gamma, and high frequency oscillations-are known to play key roles in Parkinsonian neurophysiology [25] [26] [27] [28] [29] [30] [31] [32] and potentially interact in clinically meaningful ways, such as phase-amplitude coupling [25, 28, 31, 33] . These observations suggest a need to more holistically interpret the anatomical and electrophysiological loci of STN DBS intervention to better understand optimal physiological sites of action.
Here, we analyze fully individualized anisotropic models of therapeutic tissue activation alongside high-density, broadband electrophysiology. We bring together these complementary modes of study into a unified analysis of therapeutic stimulation, by mapping microelectrode recordings to clinically-derived tissue activation models. By incorporating individual heterogeneous anisotropy into our models, we achieve precise patient-specific estimates of tissue activation [34, 35] . We describe a data-driven approach to identify associations between regions of therapeutic tissue activation and broadband electrophysiological features, including crossfrequency interactions. We then show that selected signal features can be used to accurately predict spans of therapeutic activation in a test set of data. 
Materials and methods

Patients
DBS Lead Placement
Patients underwent frame-based awake DBS surgery with microelectrode recording. Planned targets were initially assigned from indirect targeting (12 mm lateral, 3 mm posterior, and 4 mm inferior to the mid-commissural point), with adjustment from direct magnetic resonance visualization of the ventral border of STN, on 3T MRI (field of view = 200 mm x 200 mm, 0.69
x 0.69 x 1.25 mm voxels) (Philips Achieva 3T; Philips, Amsterdam, Netherlands). Recordings were performed from 15 mm above to 5 mm below the planned target on a single trajectory.
Microelectrode signals were recorded at the tip of a bipolar microelectrode (MicroTargeting Electrode; FHC, Bowdin, ME), amplified (D360 Isolated Patient Amplifier System; Digitimer, Hertfordshire, England), and recorded to a computer using custom software (LabVIEW 2015; National Instruments, Austin, TX). An electrophysiologist identified the dorsal and ventral borders of the STN during surgery. DBS leads were then inserted with the tip near the ventral border of the electrophysiologically identified STN. Intraoperative confirmation of the microelectrode trajectory and DBS lead placement were performed using fluoroscopy.
Additional details of the surgical procedure are described in previous publications [36, 37] .
Location of DBS Electrode Contacts
Tissue Activation Modeling
Preoperative diffusion tensor imaging (DTI) data for each patient were acquired using a singleshot echo planar imaging sequence with a dS-SENSE parallel-imaging scheme (reduction factor = 2, field of view = 224 mm x 224 mm, 1 x 1 x 2 mm voxels). Diffusion weighting was encoded along 16 independent orientations with a b-value of 800 s/mm². DTI images were resampled via cubic spline interpolation to match the resolution of the MRI images and oriented in Talairach space via coregistration to the Talairach-oriented MRI images in Analyze (Analyze 12.0; Mayo Clinic, Rochester, MN). The Analyze software DTI application was used to calculate the eigenvectors and eigenvalues of the DTI images. Diffusion tensors were then calculated from the eigenvectors and eigenvalues in MATLAB (MATLAB R2018b; MathWorks, Natick, MA) and converted to conductivity tensors using the linear relationship between conductivity and diffusion tensor eigenvalues (σ/d ≈0.844 S·s/mm 3 ) as described by Tuch et al. [38] .
3D finite element models of therapeutic DBS were constructed for each patient in COMSOL (Multiphysics 5.2; COMSOL, Burlington, MA), incorporating each patient's entire MRI scan, the DBS lead, and clinically-determined stimulation parameters. Brain tissue was modeled as a block with DTI-derived anisotropic conductivity tensors linearly interpolated onto the adaptive mesh. The lead was modeled as an isotropically conductive Medtronic DBS lead, model 3389, (contact: 1.4×10 7 S/m; insulation: 1×10 -13 S/m) [39, 40] positioned to match the coordinates of each patient's implanted DBS contacts, as measured from post-operative CT.
Boundary conditions were defined for the DBS electrode and bulk tissue. Specifically, an electric potential was applied to the surface of the active contact(s) according to programmed stimulation parameters of each patient, floating potentials were applied to the surfaces of the remaining contacts, and ground was applied to the surface of the brain tissue. Each patient's finite element model was meshed once individually, with finer meshing applied near the lead. Simulations were then run to solve for the electric potential in each model. The models were electrostatic, assuming frequency-independent gray matter impedance [41] .
Tissue activation volumes (VTAs) were generated for each patient in COMSOL by calculating the spatial derivative of the electric potential [42, 43] with activation thresholding at the level corresponding to each patient's clinical stimulation amplitude [44] .
Microelectrode Recording
Wideband (0.1 Hz -15 kHz) spiking activity and field potentials were recorded along the DBS probe trajectory at 0.5 mm intervals, spanning from 15 mm above to 5 mm below the surgical target (the STN ventral border on imaging), using the microelectrode recording tip. A typical trajectory traverses thalamus, field of Forel, zona incerta, subthalamic nucleus, and substantia nigra. Seven seconds of uninterrupted electrophysiology was recorded at each site, with the first second of recording removed from analysis to eliminate movement artifact. Each trajectory had electrophysiology recorded at 30 to 48 sites. Microelectrode recordings less than 5 mm from the starting depth, which may have been affected by the cannula, were excluded from analysis.
Recorded signal at each site was also visually examined for extraneous noise and excluded from analysis if found to be noisy. Data from 9 trajectories out of 32 implants were unavailable or excluded due to presence of significant noise. In total, microelectrode data from 641 sites were bands [45] . In addition to main effects, first order interaction terms, calculated as the product of each pair of covariates, e.g., log(beta power) x log(low gamma power), were also considered during analysis. Spike rate was calculated by high pass filtering the microelectrode recording at 300 Hz and counting the number of threshold crossings at 4.5 times the signal's root mean square. For analysis of oscillations, spectra of each microelectrode recording were estimated using the fast Fourier transform. To remove 60 cycle noise, spectra values within 2.5 Hz of each 60 Hz harmonic was replaced with the median power within 5 Hz of the harmonic.
Classifier Design and Validation
Predictive electrophysiological parameters for forecasting of VTA spans were identified using logistic least absolute shrinkage and selection operator (logistic LASSO). LASSO is a wellestablished regression method that removes uninformative covariates from linear models, thereby selecting for features that provide predictive value [46] . This was carried out using MATLAB's built-in lassoglm() function. The function requires a regularization parameter, λ, which determines the penalization of non-zero slopes. A parameter sweep of λ was used to determine the optimal value of λ to minimize divergence observed in 300-fold cross validation.
The final λ value used for parameter selection was one standard deviation greater than the optimal value to prevent overfitting, following the one standard error rule for model selection [47] . Parameterization of LASSO and covariate selection were performed using a training set of the data comprised of sites along 17 lead trajectories in 13 patients (out of a total of 23 implants in 16 patients), consisting of 486 sites.
The final classifier was a support vector machine (SVM) [48] , used due to its robustness to extreme values which are often observed in electrophysiological data. The classifier incorporated the covariates identified by logistic LASSO, along with the first order terms implicated by selected interaction terms. The SVM was trained on the training data set using the MATLAB built-in fitcsvm() function, with a one standard deviation box constraint (to prevent overfitting to outliers) and assumption of uniform prior probabilities. (Since there are many more sites sampled outside of therapeutic VTAs than inside, an SVM trained on empirical prior probabilities will be biased toward classifying points as non-VTA.) Notably, the classifier analyzed each site independently, predicting whether it was inside or outside of the clinically-determined VTA, using electrophysiological features recorded at that site alone ( Figure 1A ). The microelectrode recording from each site was analyzed independently of all other sites, without any spatial, trajectory, or subject information included in the analysis. Binary classifications from the SVM at each site were then spatially smoothed with a Gaussian window (σ=1 mm) to produce a probabilistic prediction spanning the DBS lead trajectory ( Figure 1B) . Performance of the smoothed prediction was characterized by a receiver-operator characteristic curve.
Performance of the SVM classifiers were determined using a holdout set of data comprised of electrophysiology from 155 sites (from six lead trajectories in three randomly selected patients not included in the training set). As such, classifier design and validation were achieved using wholly separate sets of data. This was done to ensure that classifier performance is not a result of overfitting to the training data.
The optimized SVM classifier was compared to both a beta-only classifier and a simple STN border-based approach to targeting and programing. The STN border approach assumes 2.8 V (cohort average) monopolar stimulation at the dorsal border of STN, identified in the microelectrode recording by an experienced clinical electrophysiologist. This passive approach to programming activates 2.0 mm of tissue in each direction along the span of the DBS lead (observed in two implants with 2.8 V monopolar stimulation).
Statistical Analysis
All statistical tests were performed using MATLAB software. Statistical validation of classifier performance was determined using Fisher's exact test. Classifiers were compared using the McNemar test. Performance metrics are assessed using test data. 
Results
Lead Placement and Tissue Activation Locations
Predictive Electrophysiological Features
A parameter sweep was used to determine the most appropriate regularization constant for logistic LASSO regression of VTA spans against microelectrode recordings. The sweep, performed using 300-fold cross-validation on the training set of 486 sites, yielded an optimal regularization constant of λ=0.00633, with a standard deviation of 0.0308. Details of the parameter sweep are shown in Supplementary Figure 1 . Re-running LASSO with a regularization constant equal to the optimal value plus the standard deviation (λ=0.0591) identified five predictive neural features: HFB, theta x HFB, alpha x beta, beta x HFB, and high gamma x HFO. The main effects implicated by the interaction terms-theta, alpha, beta, high gamma, and HFO-were included as predictors for subsequent classifier analysis.
Support Vector Machine Predictions
A support vector machine classifier was used to predict therapeutic tissue activation sites using ten electrophysiological features: theta, alpha, beta, high gamma, HFO, HFB, theta x HFB, alpha
x beta, beta x HFB, and high gamma x HFO. The binary classifier achieved 77% accuracy, with 64% sensitivity and 82% specificity on the test set of 155 independently analyzed sites (Table 1) .
Performance was significantly above chance with an odds ratio of 8.4 (Fisher's exact test: p<10 -6 ; 95% confidence interval: 3.8-18.5). Leave-one-out cross-validation (COOCV) (partitioned by implant) of the support vector machine achieved similar overall performance. Binary predictions and VTA models for each trajectory analyzed in this study can be seen in Supplementary Figure   2 . This model outperformed both a beta-only classifier (McNemar's test: p<10 -6 ) and the STN border-based approach to targeting and programming (McNemar's test: p=0.1175) ( Table 1) . Performance of the model was also evaluated against classifiers using individual frequency bands and a classifier using all available covariates (Supplementary Table 1 ). The model using LASSO-selected covariates achieved greater predictive value than all other classifiers. The HFB and spike rate-only classifiers were the highest-performing alternative models, both with accuracies of 74%.
While therapeutic activation sites may exist as isolated regions throughout the STN region,
VTAs generated by conventional leads must be contiguous in space. To yield a more clinically useful prediction of VTA span reflecting this possibility, binary classifications of individually analyzed points were smoothed with a Gaussian window (σ=1 mm) to be graded over space ( Figure 2 ). The smoothed predictions yielded probabilistic scores with an AUC of 0.87 for the test data (Figure 3 ). Examination of individual trajectories in Figure 2 reveals that classifier performance can vary by implant, with some predictions fully concordant with modeled VTAs, while others exhibit only slight overlap.
Interpretation of Covariate Effects
In the SVM classifier, higher values of beta, HFB (500-2000 Hz), and theta x HFB were positive predictors of therapeutic VTAs, while higher values of theta, alpha, high gamma, HFO, theta x HFB, alpha x beta, beta x HFB, and high gamma x HFO were negative predictors. In general, single covariates were insufficient to accurately forecast effective sites of tissue activation along the DBS trajectory.
Of particular interest was the predictive effect of beta. Plotting beta power against HFB ( Figure   4A ) shows that elevated beta is a positive predictor of therapeutic activation sites, but only in the presence of high HFB. Sites with high beta are not activated by therapeutic stimulation when observed with low HFB. HFB-theta interactions show a different effect: low theta power is a positive predictor of therapeutic activation when coincident with high HFB power ( Figure 4B ).
As HFB is an indicator of STN multiunit activity [49] , these interactions indicate that high beta and low theta power are positive predictors of therapeutic activation only within the STN.
Overlapping regions of VTA and non-VTA sites show that these covariates must still be interpreted alongside other bands of interest to generate reliable predictions. Alpha-beta and high gamma-HFO interactions were also identified as predictors of therapeutic activation. While the nature of interactions between these oscillations and their relation to VTAs is unclear from visual analysis, the high covariance observed between these pairs of covariates is notable ( Figure 4C -D).
Discussion
This study yields three notable findings. First, we used atlas-independent, fully individualized patient VTA models to show that clinically effective tissue activation volumes can span a variety beta and HFO are associated primarily with bradykinesia and rigidity, while gamma and alpha oscillations are more often associated with other motor manifestations and affective components of Parkinson disease [26, 27, 50] . Likewise, subthalamic theta activity has been causally linked to Parkinsonian tremor [51] . Together, these separate frequency bands may independently contribute information about different dimensions of Parkinsonism, each of which can be acted upon by therapeutic DBS. In contrast, HFB power represents STN multiunit activity and therefore provides primarily anatomical information [49] . Evaluation of an HFB-only classifier reveals high predictive value in this anatomical information, as expected from the wellestablished practice of targeting STN. Other frequency bands likely contribute information to more precisely identify therapeutic activation sites within and adjacent to STN. Notably, spike rate was not selected as a predictive feature of therapeutic VTAs, despite the unique spiking activity of STN. Its exclusion from the LASSO model is likely due to spiking rate's high covariance with HFO and HFB [52, 53] , which reduces the amount of predictive information it contributes to the model. Elevated spike rate is also often observed in thalamus, which is rarely activated by STN DBS, further reducing its contribution to the predictive model. Note, however, that the microelectrode features used in this study are extracted from only six seconds of recording at each site, which may neglect phenomena that occur at longer time scales and limit the quality of spectral estimation used for other features.
Interaction terms selected by LASSO must be carefully interpreted. The HFB interaction terms identified here provide anatomical context for interpretation of beta and theta power, by restricting their predictive value to sites within STN. Interpretation of the alpha-beta interaction is less obvious. Stein and Bar-Gad [14] suggest that perhaps a single physiologically important oscillation is captured by both alpha and beta bands, in concordance with the high covariance of alpha and beta observed in our data, which the model corrects for using the interaction term.
There also exists some evidence that the two bands together are directly linked to presentation of parkinsonian tremor [54] . Similar phenomena may also explain inclusion of the high gamma-HFO interaction in the LASSO model. Perhaps surprisingly, beta-gamma and beta-HFO interactions were excluded. This is likely due to the complex nature of described interactions between beta and high frequency oscillations [31, 33] , which would not be captured by the simplistic metric used here.
Looking ahead, the prominence of multi-frequency interactions identified and validated here strongly points to avenues of future study. Telkes et al. [32] recently demonstrated that information in beta must be fused with high frequency bands to accurately predict optimal implantation tracks. While the interactions analyzed in this study and by Telkes indicate only that power across frequency bands should be jointly assessed in the predictive model, there also exist more complex measures of interaction that may provide valuable additional information.
Sophisticated multi-frequency phenomena, such as phase-amplitude coupling [28, 33] and beta burst length [55] , have demonstrated physiological relevance. While the regression-based approach described here is unsuitable for analysis of these predictors, the cross-frequency features identified here and in other studies highlight the importance of investigating different components of broadband electrophysiology in concert.
Anatomically, we used atlas-independent, fully individualized VTA models to show that therapeutic effect can be achieved with tissue activation across a variety of sites both within and outside the STN borders. Most therapeutic VTAs activated regions within and above STN, which can be largely achieved with 2.8 V stimulation at dorsal STN. This is in line with prior work pointing to dorsolateral STN as an optimal site of stimulation [3, 4] . STN border-based programming was outperformed by microelectrode predictions, although the difference was not statistically significant. However, nuances in performance of the STN border approach necessitate important caveats to this finding. The low positive predictive value (0.45) of STN border-based programming suggests that it activates a large portion of tissue that need not be stimulated for therapeutic effect. Furthermore, the specificity of the approach is likely overestimated. Although key sites of therapeutic activation may be distinct, conventional VTAs must be spatially contiguous, activating neighboring regions. Thus, STN border-based programming and the therapeutic VTAs used for reference exhibit the same systematic error, artifactually inflating the measured specificity. When interpreted together with the anatomical diversity of therapeutic activation regions observed across subjects, as reported by earlier studies [24, 56] , these findings support opportunities for additional refinement of DBS targeting and personalized stimulation.
Although this study treats therapeutic tissue activation as a binary variable, presentations of Parkinson disease and its response to STN DBS are known to be multidimensional and varied across patients. A robust body of work suggests that different symptoms may be optimally treated by activation of different subthalamic regions and neural pathways with unique electrophysiological markers [20, 26, 57, 58] . In this view, it is critical to consider the full span of activated tissue when identifying neural markers of DBS targets, as therapy is likely achieved through activation of multiple sites with distinct electrophysiological signatures. Recent work by Telkes et al. [25] showed that different motor subtypes of Parkinson disease present with unique multiband signatures in spatially distinct STN regions. Close examination of results in Figure 2 reveal large variations in classifier performance between individual implants, suggesting that this phenomenon is likely present in the current study as well. These observations demonstrate the significant potential for further progress in this area. Future work will directly examine these relationships and their utility in treatment optimization.
It is important to note that the analysis here must be understood within the context of some fundamental limitations of the methodology. The spatially contiguous nature of VTAs guarantees that the clinically determined sites of therapeutic activation are biased to include non-therapeutic regions adjacent to clinically important sites of activation. This intrinsic error in our designation of therapeutic activation regions likely introduces significant noise into the algorithm, both in design and validation. Also, the spatial relationship between recorded oscillations and the corresponding synchronous neural population is both imprecise and incompletely understood [59, 60] , limiting the precision of microelectrode predictions. Spatially smoothing the predictions in this study provided an informative but imperfect remedy for these sources of imprecision.
More generally, it should be noted that tissue activation modeling is complex and makes several specific assumptions. This study utilizes fully individualized anisotropic conductivities and simple activation thresholds to calculate precise patient-specific VTAs. Alternative approaches, such as those employing explicit axon models [61] and driving force calculations [62] , may yield different therapeutic activation volumes [63] . At the same time, literature suggests that incorporation of tissue heterogeneity and anisotropy generates reliable activation models [34, 35] . Small errors in image co-registration and lead movement after implantation may also introduce errors into our analysis.
Nonetheless, by predicting both the approximate location and span of generalized therapeutic tissue activation volumes, the approach presented here can be used to quickly estimate effective sites and amplitudes of stimulation. Perhaps more importantly, this method significantly restricts the parameter space that must be explored to optimize DBS stimulation parameters. With the introduction of directional DBS leads promising greater therapeutic windows [64] [65] [66] , new tools such as the one presented here are needed to constrain the greatly expanded parameter space of directional leads to efficiently interrogate potential program settings. Eventually, such targeting methods may be used in concert with parameter optimization algorithms [67] [68] [69] [70] [71] , potentially achieving even greater STN DBS programming efficiency. Classifier performance using the full model determined by LASSO and using a beta-only model. PPV = positive predictive value; NPV = negative predictive value; LOOCV = leave-one-out cross-validation
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